Progress in drug treatment for tumors of the nervous system ‒ including primary tumors and metastases due to tumors from other sites ‒ has been slow due to the difficulty of crossing the blood-brain barrier and the heterogeneity of cancer cells. Bur in recent years, targeted, immune, and other therapies have brought new hope. Because of the unique nature of the emergence and progression of brain tumors, there is still discussion on how to develop the best workflow for evaluating the efficacy of brain tumor treatments in clinical trials.
In this workshop Calyx will share more than 25 years’ experience in imaging evaluation in neurological tumor trials
– Medical Imaging Considerations in Clinical Trials
– Evaluation of Glioma – RANO criteria
– Evaluation of brain metastases – RANO-BM criteria
时间
2022 年 6 月 8 日
8PM-9PM Beijing Time
发言人
Yibin Shao
Medical Director, Calyx MI
Currently leading the Medical Sciences Department at Calyx China, Yibin has extensive clinical trial and medical imaging experience, has supported over 100 BICR services for registration filing trials. She is a senior expert in the implementation and standardization of evaluation standards such as RECIST, iRECIST, IWG, Lugano, PCWG, mRECIST, RANO, etc.
